Kabra Drugs Limited: Soaring Profits Signal Strategic Milestones

Chennai, India, February 17, 2026 – Kabra Drugs Limited (BSE: 524322) has reported a remarkable 578% spike in Profit After Tax compared to the previous year. The microcap company announced its unaudited financial results on February 13, 2026, for the quarter ending December 31, 2025, marking a significant corporate turnaround.

The company's revenue for the December quarter hit ₹30.42 crore, a striking 53.9% rise from the September 2025 quarter and a significant recovery from nil revenue in December 2024. Kabra Drugs has experienced a strong investor rally, driving its stock nearly 200% upward in a year.

Strategically, Kabra Drugs is diversifying into high-growth areas, including the manufacturing of medical equipment. An agreement with MR Franchise has been signed to appoint 200 channel partners, expanding its market reach. A proposed name change is in consideration to align with the company's evolving business model, pending shareholder and regulatory approval.